Dual attendance for Cellply at March’s leading events in the cell therapy industry.

After the official launch of VivaCyte® in January at the Advance Therapies Week in Miami, Cellply will be attending two simultaneous events in March to showcase its platform’s innumerable capabilities.

Through VivaCyte it’s possible to calculate a Unified Potency Score.

For each donor and for each effector cell population, we can define its serial killing ability as the % of effector cells that were able to kill a certain number of target cell in a certain amount of time, with reference to a specific target cell line.